Ascentage Pharma Group International

Informe acción SEHK:6855

Capitalización de mercado: HK$14.2b

Ascentage Pharma Group International Resultados de beneficios anteriores

Pasado controles de criterios 0/6

Ascentage Pharma Group International has been growing earnings at an average annual rate of 10.4%, while the Biotechs industry saw earnings growing at 31.7% annually. Revenues have been growing at an average rate of 73.2% per year.

Información clave

10.4%

Tasa de crecimiento de los beneficios

29.5%

Tasa de crecimiento del BPA

Crecimiento de la industria Biotechs 11.0%
Tasa de crecimiento de los ingresos73.2%
Rentabilidad financiera-46.4%
Margen neto-39.9%
Última actualización de beneficios30 Jun 2024

Actualizaciones de resultados anteriores recientes

Recent updates

Ascentage Pharma Group International's (HKG:6855) Shares Climb 26% But Its Business Is Yet to Catch Up

Sep 04
Ascentage Pharma Group International's (HKG:6855) Shares Climb 26% But Its Business Is Yet to Catch Up

Here's Why Ascentage Pharma Group International (HKG:6855) Can Afford Some Debt

Aug 26
Here's Why Ascentage Pharma Group International (HKG:6855) Can Afford Some Debt

Ascentage Pharma Group International's (HKG:6855) Shares Climb 29% But Its Business Is Yet to Catch Up

Jun 18
Ascentage Pharma Group International's (HKG:6855) Shares Climb 29% But Its Business Is Yet to Catch Up

Here's Why Ascentage Pharma Group International's (HKG:6855) CEO May Not Expect A Pay Rise This Year

May 03
Here's Why Ascentage Pharma Group International's (HKG:6855) CEO May Not Expect A Pay Rise This Year

Why We're Not Concerned Yet About Ascentage Pharma Group International's (HKG:6855) 30% Share Price Plunge

Mar 30
Why We're Not Concerned Yet About Ascentage Pharma Group International's (HKG:6855) 30% Share Price Plunge

Are Investors Undervaluing Ascentage Pharma Group International (HKG:6855) By 40%?

Feb 17
Are Investors Undervaluing Ascentage Pharma Group International (HKG:6855) By 40%?

There's Reason For Concern Over Ascentage Pharma Group International's (HKG:6855) Price

Dec 20
There's Reason For Concern Over Ascentage Pharma Group International's (HKG:6855) Price

Ascentage Pharma Group International (HKG:6855) Is Making Moderate Use Of Debt

Oct 28
Ascentage Pharma Group International (HKG:6855) Is Making Moderate Use Of Debt

Some Analysts Just Cut Their Ascentage Pharma Group International (HKG:6855) Estimates

Aug 27
Some Analysts Just Cut Their Ascentage Pharma Group International (HKG:6855) Estimates

There's Reason For Concern Over Ascentage Pharma Group International's (HKG:6855) Price

Aug 23
There's Reason For Concern Over Ascentage Pharma Group International's (HKG:6855) Price

Ascentage Pharma Group International (HKG:6855) Is Carrying A Fair Bit Of Debt

Jun 19
Ascentage Pharma Group International (HKG:6855) Is Carrying A Fair Bit Of Debt

Ascentage Pharma Group International (HKG:6855) Has Debt But No Earnings; Should You Worry?

Dec 04
Ascentage Pharma Group International (HKG:6855) Has Debt But No Earnings; Should You Worry?

Is Ascentage Pharma Group International (HKG:6855) A Risky Investment?

Aug 30
Is Ascentage Pharma Group International (HKG:6855) A Risky Investment?

Does Ascentage Pharma Group International (HKG:6855) Have A Healthy Balance Sheet?

Oct 04
Does Ascentage Pharma Group International (HKG:6855) Have A Healthy Balance Sheet?

Desglose de ingresos y gastos

Cómo gana y gasta dinero Ascentage Pharma Group International. Basado en los últimos beneficios reportados, en base a los últimos doce meses (LTM).


Historial de beneficios e ingresos

SEHK:6855 Ingresos, gastos y beneficios (CNY Millions)
FechaIngresosBeneficiosGastos G+AGastos de I+D
30 Jun 24903-360378841
31 Mar 24563-643377774
31 Dec 23222-926376707
30 Sep 23239-902363709
30 Jun 23257-879349712
31 Mar 23233-881339727
31 Dec 22210-883328743
30 Sep 22160-848299767
30 Jun 22111-812270790
31 Mar 2269-797231778
31 Dec 2128-782191766
30 Sep 2125-759167699
30 Jun 2123-735143631
31 Mar 2118-706137598
31 Dec 2012-678130565
30 Sep 2014-922146540
30 Jun 2015-1,167162516
31 Mar 2015-1,324162490
31 Dec 1915-1,481162464
30 Sep 1911-1,171133418
30 Jun 197-862104372
31 Mar 197-60497311
31 Dec 187-34590250
31 Dec 176-11926119
31 Dec 168-10822103

Ingresos de calidad: 6855 is currently unprofitable.

Margen de beneficios creciente: 6855 is currently unprofitable.


Análisis del flujo de caja libre vs. Beneficios


Análisis del crecimiento de los beneficios en el pasado

Tendencia de beneficios: 6855 is unprofitable, but has reduced losses over the past 5 years at a rate of 10.4% per year.

Acelerando crecimiento: Unable to compare 6855's earnings growth over the past year to its 5-year average as it is currently unprofitable

Beneficios vs. Industria: 6855 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (5.5%).


Rentabilidad financiera

Alta ROE: 6855 has a negative Return on Equity (-46.43%), as it is currently unprofitable.


Rentabilidad económica


Rendimiento del capital invertido


Descubre empresas con buenos resultados en el pasado